EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tigecycline Opposes Bortezomib Effect on Myeloma Cells Decreasing Mitochondrial Reactive Oxygen Species Production

Carlos Ramos-Acosta, Laura Huerta-Pantoja, Milton Eduardo Salazar-Hidalgo iD, Elsa Mayol, Selene Jiménez-Vega iD, Pablo García-Peña, Jenifeer Jordi-Cruz, Cristina Baquero, Almudena Porras iD, Belén Íñigo-Rodríguez, Celina M Benavente, Andrea R López-Pastor und 4 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25094887 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Carlos Ramos-Acosta und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Medical School, Universidad Complutense de Madrid (UCM), Plaza Ramón y Cajal s/n, 28040 Madrid, Spain. Hauptthemen laut MEDLINE: Bortezomib, Multiple Myeloma, Tigecycline, Mitochondria. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundación Hay Esperanza, Fundación Leucemia y Linfoma and Fundación Vistare, Celgene International.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma is an incurable plasma cell malignancy. Most patients end up relapsing and developing resistance to antineoplastic drugs, like bortezomib. Antibiotic tigecycline has activity against myeloma. This study analyzed tigecycline and bortezomib combination on cell lines and plasma cells from myeloma patients. Apoptosis, autophagic vesicles, mitochondrial mass, mitochondrial superoxide, cell cycle, and hydrogen peroxide were studied by flow cytometry. In addition, mitochondrial antioxidants and electron transport chain complexes were quantified by reverse transcription real-time PCR (RT-qPCR) or western blot. Cell metabolism and mitochondrial activity were characterized by Seahorse and RT-qPCR. We found that the addition of tigecycline to bortezomib reduces apoptosis in proportion to tigecycline concentration. Supporting this, the combination of both drugs counteracts bortezomib in vitro individual effects on the cell cycle, reduces autophagy and mitophagy markers, and reverts bortezomib-induced increase in mitochondrial superoxide. Changes in mitochondrial homeostasis and MYC upregulation may account for some of these findings. These data not only advise to avoid considering tigecycline and bortezomib combination for treating myeloma, but caution on the potential adverse impact of treating infections with this antibiotic in myeloma patients under bortezomib treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BortezomibMultiple MyelomaTigecyclineMitochondriaReactive Oxygen SpeciesApoptosisHumansCell Line, TumorAntineoplastic AgentsAutophagyMitophagyCell Cycle

Stichwörter der Autor:innen

ROSantagonismbortezomibcell cyclemultiple myelomatigecycline

Substanzen

BortezomibTigecyclineReactive Oxygen SpeciesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Medicine, Medical School, Universidad Complutense de Madrid (UCM), Plaza Ramón y Cajal s/n, 28040 Madrid, Spain.
  • Hematology Department, IML, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, Profesor Martín Lagos s/n, 28040 Madrid, Spain.
  • Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Universidad Complutense de Madrid (UCM), Instituto de Investigación Sanitaria San Carlos (IdISSC), 28040 Madrid, Spain.
  • Laboratory of Genetics and Molecular Bases of Complex Diseases, Instituto de Investigación Sanitaria San Carlos (IdISSC), 28040 Madrid, Spain.
  • Networks for Cooperative Research in Health Results (RICORS, REI), 28089 Madrid, Spain.
  • Clinical Microbiology & Infectious Diseases, Transplant Coordination, IML, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, 28040 Madrid, Spain.

ORCID-Profile: Milton Eduardo Salazar-Hidalgo, Selene Jiménez-Vega, Almudena Porras, Irene Gómez-Delgado, Elena Urcelay, Eduardo Anguita

Förderung

  • Fundación Hay Esperanza
  • Fundación Leucemia y Linfoma and Fundación Vistare
  • Celgene International

Zitieren

APA

Ramos-Acosta, C., Huerta-Pantoja, L., Salazar-Hidalgo, M. E., Mayol, E., Jiménez-Vega, S., García-Peña, P., Jordi-Cruz, J., Baquero, C., Porras, A., Íñigo-Rodríguez, B., Benavente, C. M., López-Pastor, A. R., Gómez-Delgado, I., Urcelay, E., Candel, F. J., & Anguita, E. (2024). Tigecycline Opposes Bortezomib Effect on Myeloma Cells Decreasing Mitochondrial Reactive Oxygen Species Production. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25094887

Vancouver

Ramos-Acosta C, Huerta-Pantoja L, Salazar-Hidalgo ME, Mayol E, Jiménez-Vega S, García-Peña P, et al. Tigecycline Opposes Bortezomib Effect on Myeloma Cells Decreasing Mitochondrial Reactive Oxygen Species Production. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25094887

BibTeX
@article{RamosAcosta2024,
  author = {Ramos-Acosta, Carlos and Huerta-Pantoja, Laura and Salazar-Hidalgo, Milton Eduardo and Mayol, Elsa and Jiménez-Vega, Selene and García-Peña, Pablo and Jordi-Cruz, Jenifeer and Baquero, Cristina and Porras, Almudena and Íñigo-Rodríguez, Belén and Benavente, Celina M and López-Pastor, Andrea R and Gómez-Delgado, Irene and Urcelay, Elena and Candel, Francisco Javier and Anguita, Eduardo},
  title = {Tigecycline Opposes Bortezomib Effect on Myeloma Cells Decreasing Mitochondrial Reactive Oxygen Species Production},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25094887}
}
Kostenlos starten →